News Release

和其瑞医药宣布子宫内膜异位症全球临床二期试验中国首例患者开始给药

和其瑞医药任命陈曦为首席执行官

和其瑞医药宣布首创单抗新药HMI-115获得治疗子宫内膜异位症的 中国临床二期试验批准

Circ Res 北京大学肖瑞平教授团队揭示阻断MG53 S255磷酸化可以保护糖尿病心脏免受缺血性损伤

Hope Medicine Announces US FDA Clearance for Phase II Clinical Trial of A First-in-class Monoclonal Antibody, HMI-115, in AGA Alopecia

Hope Medicine completed US$56 million in Series B financing, strengthening capabilities of global innovation